|1.||Molina, Arturo: 28 articles (11/2015 - 04/2009)|
|2.||de Bono, Johann S: 26 articles (11/2015 - 10/2008)|
|3.||Ryan, Charles J: 22 articles (11/2015 - 03/2010)|
|4.||Attard, Gerhardt: 20 articles (11/2015 - 10/2008)|
|5.||Kheoh, Thian: 20 articles (11/2015 - 08/2009)|
|6.||Scher, Howard I: 15 articles (10/2015 - 10/2009)|
|7.||Fizazi, Karim: 14 articles (11/2015 - 05/2011)|
|8.||Saad, Fred: 14 articles (10/2015 - 05/2011)|
|9.||Logothetis, Christopher J: 13 articles (10/2015 - 05/2011)|
|10.||Small, Eric J: 12 articles (10/2015 - 03/2010)|
|1.||Prostatic Neoplasms (Prostate Cancer)
01/01/2014 - "Newly approved chemotherapeutic agents such as Abiraterone (an oral selective inhibitor of CYP17A), which blocks androgen biosynthesis both within and outside the prostate cancer cells), and enzalutamide (blocks AR signaling) have improved overall survival. "
06/01/2014 - "The orally-active CYP17A1 inhibitor abiraterone acetate (AA) decreases adrenal and intratumoral androgen biosynthesis and is an effective agent for the treatment of prostate cancer. "
07/01/2014 - "New drugs that inhibit the steroidogenic enzyme CYP17A1 (abiraterone acetate) or diminish nuclear translocation of the AR (enzalutamide) have been shown to improve patients' survival in prostate cancer. "
12/15/2015 - "In vitro proliferation studies demonstrated single-agent doses between 2 μmol/L and 10 μmol/L for abiraterone and cabozantinib inhibit prostate cancer cell proliferation in a dose-dependent manner, and the anticancer activity of abiraterone is enhanced when combined with cabozantinib. "
07/01/2015 - "Prospective, non-interventional trial on the influence of adherence to abiraterone treatment in patients with metastatic, castrate-resistant prostate cancer (IMPACT) - trial AP 76/13 of the AUO]."
01/01/2013 - "Contemporary therapeutic options including enzalutamide and abiraterone have effects on pain palliation and SREs as well. "
02/01/2014 - "Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death."
06/01/2015 - "After the treatment with abiraterone, patient's performance status improved, pain relieved, total prostate specific antigen (tPSA) and free prostate specific antigen (fPSA) markedly decreased. "
01/01/2016 - "RaTot, ALP, initial ECOG status, initial pain score, and use of abiraterone were associated with OS (p ≤ 0.008), PFS (p ≤ 0.003), and BeFS (p ≤ 0.020). "
11/01/2013 - "Median time to progression of worst pain was also longer with abiraterone plus prednisone (26·7 months [95% CI 19·4-not estimable]) than with placebo plus prednisone (19·4 months [16·6-not estimable]), but the difference was not significant (HR 0·85, 95% CI 0·69-1·04; p=0·109). "
07/01/2014 - "Three open-label, single-dose studies investigated the impact of hepatic or renal impairment on abiraterone acetate pharmacokinetics and safety/tolerability in non-cancer patients. "
11/01/2013 - "Here we report on the impact of abiraterone therapy on the health-related quality of life (HRQoL) observed during this trial, assessed using the validated Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. "
11/04/2015 - "Evaluation of plasma AR by next-generation sequencing could identify cancers with primary resistance to abiraterone. "
11/04/2015 - "Whereas AR copy number was unchanged from before treatment to progression and no mutant AR alleles showed signal for acquired gain, we observed emergence of T878A or L702H AR amino acid changes in 13% of tumors at progression on abiraterone. "
06/01/2015 - "This review explores key stages in the almost 20-year history of abiraterone acetate׳s development, starting with a program aiming to develop inhibitors of androgen synthesis at the Institute of Cancer Research, London. "
07/01/2012 - "Abiraterone provides a moderate improvement in disease progression and mortality in a patient population with limited treatment options. "
08/01/2015 - "Although this was a retrospective study with a small sample size, we did not observe any statistically significant differences in the clinical response to abiraterone acetate between mCRPC patients with long ADT duration and those with short ADT duration in terms of disease progression-free survival."
05/15/2015 - "Plasma was collected from 62 mCRPC patients ceasing abiraterone acetate (n = 29), enzalutamide (n = 19), or other agents (n = 14) due to disease progression. "
08/01/2015 - "The degree of antitumour activity of enzalutamide following disease progression on docetaxel and abiraterone remains controversial. "
08/01/2015 - "We identified 15 patients had experienced disease progression with abiraterone acetate and subsequently were treated with docetaxel. "
|5.||Neoplasm Metastasis (Metastasis)
04/01/2014 - "For patients accepting these uncertainties, a trial of nonsteroidal antiandrogen may be considered as an adjunct to observation, followed by low dose corticosteroid with immediate or delayed addition of abiraterone (in men with metastases) as a reasonable next step."
10/20/2014 - "When added to androgen deprivation, therapies demonstrating improved survival, improved quality of life (QOL), and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and radium-223 ((223)Ra; for men with predominantly bone metastases). "
09/01/2014 - "Compared to subjects who received enzalutamide post-abiraterone, subjects who received docetaxel post-abiraterone had more bone metastases, more visceral metastases, higher baseline PSA, and had more frequent PSA tests while on-treatment. "
05/01/2013 - "For both patients, responses to abiraterone were noticeable within 1 month, encompassing a marked regression of visceral metastases and a decrease in prostate-specific antigen. "
12/01/2012 - "Abiraterone acetate potently disrupts intracrine androgen receptor signalling pathways implicated in the progression of the disease, including bone metastases. "
|2.||4- acetoxy- 13- ((3- ((tert- butoxycarbonyl)amino)- 2- hydroxy- 3- phenylpropanoyl)oxy)- 1- hydroxy- 7,10- dimethoxy- 9- oxo- 5,20- epoxytax- 11- en- 2- yl benzoate
|6.||Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)
|7.||Androgen Receptors (Androgen Receptor)
|8.||Prostate-Specific Antigen (Semenogelase)
|2.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)